Amphotericin B (Lipid Complex)
| Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
|---|---|---|---|
| Antifungals | Amphotericin B (Lipid Complex) | 5mg/kg IV Q24H | Administer Anytime During HD |
|
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 934 | <1 | 19-45 | Unchanged | 90 | 1.7-3.9 | N/A | 0 (high flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Block E, Bennett J, Livoti L, Klein W. Flucytosine and Amphotericin B: Hemodialysis Effects on the Plasma Concentration and Clearance. Annals of internal medicine 1974; 80, 613-7.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00681
- Feldman H, Hamilton J, Gutman R. Amphotericin B Therapy in an Anephric Patient. Antimicrobial agents and chemotherapy 1973; 4(3), 302-305.
- Gussak H, Rahman S, Bastani B. Administration and clearance of amphotericin B during high-efficiency or high-efficiency/high-flux dialysis. American Journal of Kidney Diseases 2001; 37(6), E45.
- Heinemann V, Bosse D, Jehn U et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Pharmacokinetics of Liposomal Amphotericin B (AmBisome) in Critically Ill Patients. Microbiology 1997; 41(6).
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Polak A. Pharmacokinetics of amphotericin B and flucytosine. Postgraduate medical journal 1979; 55(September), 667-670.
- Wood J, Mahnensmith M, Mahnensmith R, Perazella M. Intradialytic administration of amphotericin B: clinical observations on efficacy and safety. The American journal of the medical sciences 2004; 327(1), 5-8.